Neurocrine biosciences announces fda approval of ingrezza® (valbenazine) capsules for the treatment of chorea associated with huntington's disease

San diego , aug. 18, 2023 /prnewswire/ --  neurocrine biosciences, inc .  (nasdaq: nbix) today announced the u.s. food and drug administration (fda) has approved ingrezza® (valbenazine) capsules for the treatment of adults with chorea associated with huntington's disease (hd).1 ingrezza is the only selective vesicular monoamine transporter 2 (vmat2) inhibitor that offers an effective starting dosage that can be adjusted by a patient's healthcare provider based on response and tolerability, with no complex titration.1 only ingrezza offers simple dosing that is always one capsule, once daily.1 experience the full interactive multichannel news release here: https://www.multivu.com/players/english/9147451-neurocrine-biosciences-fda-approval-ingrezza/  the fda approval is supported by data from two clinical studies conducted in collaboration with the huntington study group (hsg), including the kinect®-hd phase 3 study and the ongoing kinect®-hd2 open-label extension trial.1,2 kinect-hd, a randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of ingrezza, met its primary endpoint of least squares mean (lsm) change in chorea severity using the total maximal chorea (tmc) score of the unified huntington's disease rating scale (uhdrs) from screening period baseline to maintenance period (average of weeks 10 and 12), demonstrating a statistically significant greater improvement in tmc score with ingrezza versus placebo.1,2  "we are proud to bring ingrezza to people living with hd and their caregivers who now have the option of a one-capsule, once-daily treatment that has demonstrated significant improvement in hd chorea in clinical studies," said kevin c.
NBIX Ratings Summary
NBIX Quant Ranking